What Is SMX Scientific Intelligence, and Can It Add a New Revenue Line for SMX (NASDAQ:SMX)?

Sonal Goyal

12 November 2026 12:12 PM AEDT

What Is SMX Scientific Intelligence, and Can It Add a New Revenue Line for SMX (NASDAQ:SMX)?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

SMX is developing SMX Scientific Intelligence, or SMX SCI, an AI-powered platform for industrial material research.
The platform is planned for internal use in the first quarter of 2027, with full operations in the second quarter.
A limited commercial edition is targeted for the second quarter, subject to development and testing.
SMX has not disclosed development costs, pricing or expected Revenue for the platform.

SMX (NASDAQ:SMX) is preparing to extend its Business into AI-powered scientific services with a planned platform called SMX Scientific Intelligence, or SMX SCI. The company, which has built its technology around molecular marking, material authentication and digital tracking, said on November 11, 2026 that the platform will first support its own research and may later be sold as a commercial service to manufacturers worldwide. Scientific services of this kind sit between laboratory work and product design, a space that industrial manufacturers often cover with outside consultants and internal test programs.

What the Platform Is Meant to Do

SMX SCI is designed to combine artificial intelligence with the company's accumulated knowledge of material science, chemical agents, molecular markers and industrial Manufacturing processes. The company describes it as an effort to build a scientific codex covering the chemical agents, additives and supplementary materials used in identification, tracking and product enhancement.

Using AI-assisted analysis, the system would evaluate chemical properties, manufacturing conditions and production requirements. The aim is to help customers identify suitable materials for specific needs and screen Options before laboratory testing begins.

Material compatibility testing is time consuming, and many manufacturers run physical trials to confirm that additives and chemical agents work together. An AI tool that narrows the options before testing could reduce the number of trials, which is the efficiency case the company is making.

Timeline and Commercial Plans

SMX plans to introduce the platform internally in the first quarter of 2027, with full operations expected in the second quarter. A limited commercial edition is also targeted for the second quarter, but the company made that target conditional on successful development and testing.

For manufacturers, the proposed service would offer a way to narrow material options before committing to physical trials. Because the commercial timetable depends on development progress, the launch date could move.

Accuracy would be central to customer adoption. Any system that recommends materials would need validation data and clear limits, and the updates do not describe how SMX plans to test the system's outputs.

Link to the Existing Business

The platform would extend SMX's portfolio beyond physical identification and digital verification into AI-assisted analysis. Its value to the company depends on whether industrial customers will pay for scientific analysis delivered as a service, which is a different proposition from identification products.

The material reviewed does not disclose the cost of developing SMX SCI, its pricing or the revenue it might generate in its first year, so its financial weight cannot be assessed.

The planned rollout sequence, internal first and commercial second, allows the company to use its own research as a proving ground before offering the platform externally. That approach is common for software that depends on proprietary data.

Development Risks and Open Questions

The commercial edition is conditional, and the updates do not describe the team, partners or data sources behind the AI system. Those details would matter to customers who need to judge the accuracy of its recommendations.

Investors and prospective customers will look for internal test results, early deployments and the cost of running the system at scale. Each of those would indicate whether the platform moves beyond its planned stage.

A commercial service would also raise questions about data protection and intellectual property, since customers may share proprietary formulations or manufacturing details. The update does not address those terms.

Final Word

SMX SCI represents a planned move from identification technology into AI-driven scientific services. Its contribution depends on a successful internal rollout in 2027, a commercial edition that reaches its targeted quarter and customers willing to pay for the analysis. Future updates on testing and early customers will show whether the platform advances beyond the planning stage. Early evidence from internal use would give the clearest sign of whether the service is commercially viable.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.